Caseware UK (AP4) 2024.0.164 2024.0.164 2025-10-312025-10-3102024-11-01false0Research and experimental development on biotechnologytruetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 13664496 2024-11-01 2025-10-31 13664496 2023-11-01 2024-10-31 13664496 2025-10-31 13664496 2024-10-31 13664496 c:Director2 2024-11-01 2025-10-31 13664496 d:OfficeEquipment 2024-11-01 2025-10-31 13664496 d:OfficeEquipment 2025-10-31 13664496 d:OfficeEquipment 2024-10-31 13664496 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-11-01 2025-10-31 13664496 d:CurrentFinancialInstruments 2025-10-31 13664496 d:CurrentFinancialInstruments 2024-10-31 13664496 d:CurrentFinancialInstruments d:WithinOneYear 2025-10-31 13664496 d:CurrentFinancialInstruments d:WithinOneYear 2024-10-31 13664496 d:ShareCapital 2025-10-31 13664496 d:ShareCapital 2024-10-31 13664496 d:RetainedEarningsAccumulatedLosses 2025-10-31 13664496 d:RetainedEarningsAccumulatedLosses 2024-10-31 13664496 c:OrdinaryShareClass1 2024-11-01 2025-10-31 13664496 c:OrdinaryShareClass1 2025-10-31 13664496 c:OrdinaryShareClass1 2024-10-31 13664496 c:FRS102 2024-11-01 2025-10-31 13664496 c:AuditExempt-NoAccountantsReport 2024-11-01 2025-10-31 13664496 c:FullAccounts 2024-11-01 2025-10-31 13664496 c:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 13664496 e:PoundSterling 2024-11-01 2025-10-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 13664496









NEW ROAD THERAPEUTICS LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 OCTOBER 2025

 
NEW ROAD THERAPEUTICS LIMITED
REGISTERED NUMBER: 13664496

BALANCE SHEET
AS AT 31 OCTOBER 2025

2025
2024
Note
£
£

FIXED ASSETS
  

Tangible assets
 4 
-
126

  
-
126

CURRENT ASSETS
  

Debtors: amounts falling due within one year
 5 
268
292

Cash at bank and in hand
  
310
2,045

  
578
2,337

Creditors: amounts falling due within one year
 6 
(6,105)
(5,045)

NET CURRENT LIABILITIES
  
 
 
(5,527)
 
 
(2,708)

TOTAL ASSETS LESS CURRENT LIABILITIES
  
(5,527)
(2,582)

  

NET LIABILITIES
  
(5,527)
(2,582)


CAPITAL AND RESERVES
  

Called up share capital 
 7 
2
2

Profit and loss account
  
(5,529)
(2,584)

  
(5,527)
(2,582)


Page 1

 
NEW ROAD THERAPEUTICS LIMITED
REGISTERED NUMBER: 13664496
    
BALANCE SHEET (CONTINUED)
AS AT 31 OCTOBER 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 





K M L Holden
Director

Date: 8 January 2026

The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
NEW ROAD THERAPEUTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

1.


GENERAL INFORMATION

New Road Therapeutics Limited is a private company, limited by shares and incorporated in England & Wales. Its registered office address is Salisbury House, Station Road, Cambridge, CB1 2LA.

The Company's functional and presentational currency is GBP. 

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

GOING CONCERN

The Company had net liabilities of £5,527 as at 31 October 2025 (2024 - £2,582). The financial statements are prepared on the going concern basis on the assumption that the Company will continue to receive financial support from its shareholders to provide sufficient funds to enable it to meet its liabilities as they fall due.

 
2.3

TURNOVER

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before turnover is recognised:

Rendering of services

Turnover from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of turnover can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 3

 
NEW ROAD THERAPEUTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.4

TAXATION

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.5

TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment
-
33%
straight-line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.6

DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Page 4

 
NEW ROAD THERAPEUTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.7

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.8

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


EMPLOYEES

The Company has no employees other than the directors, who did not receive any remuneration (2024 - £NIL).


4.


TANGIBLE FIXED ASSETS





Office equipment

£



COST OR VALUATION


At 1 November 2024
1,197



At 31 October 2025

1,197



DEPRECIATION


At 1 November 2024
1,071


Charge for the year on owned assets
126



At 31 October 2025

1,197



NET BOOK VALUE



At 31 October 2025
-



At 31 October 2024
126

Page 5

 
NEW ROAD THERAPEUTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025

5.


DEBTORS

2025
2024
£
£


Prepayments and accrued income
268
292



6.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025
2024
£
£

Other creditors
4,485
3,485

Accruals and deferred income
1,620
1,560

6,105
5,045



7.


SHARE CAPITAL

2025
2024
£
£
ALLOTTED, CALLED UP AND FULLY PAID



2 (2024 - 2) Ordinary shares shares of £1.00 each
2
2


 
Page 6